Page last updated: 2024-12-06

barbexaclone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Cross-References

ID SourceID
PubMed CID71196
SCHEMBL ID389348
MeSH IDM0057012

Synonyms (33)

Synonym
(-)-n,alpha-dimethylcyclohexaneethylamine compound with 5-ethyl-5-phenylbarbituric acid
1,1-cyclohexyl-2-methylaminopropane-5,5-phenylethylbarbiturate
barbexaclone [inn]
barbexaclona [inn-spanish]
barbexaclon
su 42
barbexaclone
barbexaclonum [inn-latin]
propylhexedrine l-form ethylphenylbarbiturate
hp-phenobarbitalat [german]
maliasin
chp-phenobarbitalat
einecs 224-504-7
barbexaclonum
barbituric acid, 1-(1-cyclohexyl-n-methyl-2-propanamine)-5-ethyl-5-phenyl-
4388-82-3
barbexaclone (inn)
D07298
maliasin (tn)
barbexaclona
291gx1yb65 ,
unii-291gx1yb65
hp-phenobarbitalat
propylhexedrine l-form ethylphenylbarbiturate [mi]
barbexaclone [who-dd]
(-)-n,a-dimethylcyclohexaneethylamine compound with 5-ethyl-5-phenylbarbituric acid
barbexaclone [mart.]
SCHEMBL389348
DTXSID90195974
DB09001
Q409549
5-ethyl-5-phenylpyrimidine-2,4,6(1h,3h,5h)-trione compound with (s)-1-cyclohexyl-n-methylpropan-2-amine (1:1)
(2s)-1-cyclohexyl-n-methylpropan-2-amine;5-ethyl-5-phenyl-1,3-diazinane-2,4,6-trione

Research Excerpts

Overview

Barbexaclone is a salt compound of phenobarbital and propylhexedrine. It is a drug with indirect sympathomimetic properties.

ExcerptReferenceRelevance
"Barbexaclone is a salt compound of phenobarbital and propylhexedrine (a drug with indirect sympathomimetic properties). "( End of the barbexaclone era: an experience of treatment withdrawal.
Bolukbasi, F; Bulus, E; Delil, S; Karaagac, N; Senturk, A; Yeni, N, 2013
)
2.22

Dosage Studied

ExcerptRelevanceReference
" The authors draw attention to the fact that there was a concomitant improvement in the behaviour of some patients and a diminution of maintainence dosage in relation to a previously published trial."( [Re-evaluation of barbexaclone in 20 epileptic patients].
de Lima, JM; Fernandes, I; Oliveira, C, 1978
)
0.59
" The mean dosage of barbexaclone was lower in patients who improved than in those who remained unchanged."( [Barbexaclone in the treatment of the epilepsies (author's transl)].
Calzetti, S; Mancia, D; Visintini, D,
)
1.37
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (20)

TimeframeStudies, This Drug (%)All Drugs %
pre-199016 (80.00)18.7374
1990's1 (5.00)18.2507
2000's1 (5.00)29.6817
2010's2 (10.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials4 (19.05%)5.53%
Reviews1 (4.76%)6.00%
Case Studies6 (28.57%)4.05%
Observational0 (0.00%)0.25%
Other10 (47.62%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]